Dexketoprofen

Dexketoprofen has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 26, 2021: “Identification and drug-induced reversion of molecular signatures of Alzheimer's disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models”.

Intervention

1 paper studies it1 more mentions it2 findingsUpdated

PubChemChEBI

See all 2 papers on dexketoprofen

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country; 4 trials, none about aging, 1 with no results posted.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • 4 trials, none about aging, 1 with no results posted
  • Funders: Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya and 7 more
  • Animals1

What did studies of dexketoprofen find?

2

Studies of dexketoprofen measured 2 outcomes: amyloid-beta plaques and cognitive impairment.

Amyloid-beta plaques

downin mice1

1 study
  1. Dexketoprofen decreases amyloid-beta plaques in AD mice.

    “reducing Aβ plaques in the hippocampus”

    Animalsin AD micehippocampus

    Identification and drug-induced reversion of molecular signatures of Alzheimer's disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models

    Genome medicine

More on Amyloid-beta plaques

Cognitive impairment

downin mice1

1 study
  1. Dexketoprofen decreases cognitive impairment in AD mice.

    “two NSAIDs (dexketoprofen and etodolac) and two anti-hypertensives (penbutolol and bendroflumethiazide) that overturn the cognitive impairment in AD mice”

    Animalsin AD micehippocampus

    Identification and drug-induced reversion of molecular signatures of Alzheimer's disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models

    Genome medicine

Who is developing dexketoprofen?

1 company: Laboratorios Silanes S.A. de C.V..

Companies
  • Laboratorios Silanes S.A. de C.V.Phase 3primary dysmenorrhea, acute low back pain

Trial sponsors

Latest